| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biochemistry, University of Health Sciences/The Chicago Medical School, Chicago, Illinois 60612
Binding of tritium-labeled monosialoganglioside (GM1) by intact thymocytes of young AKR/J mice was studied in vitro. The binding was dependent on time, temperature, concentration of cells, and ganglioside, suggesting that the cells possess a finite number of GM1-binding sites. Binding, which could be observed as early as 15 sec, was very rapid, reaching a plateau in about 5 min, followed by a slow and steady increment up to 4 hr of incubation. Cellular binding of GM1 appeared to be tight with very little exchange with exogenous gangliosides. GM1 was almost entirely recovered intact 30 min after it was bound by thymus cells. The structural components of GM1 (galactose, glucose, N-acetylneuraminic acid, mixed ceramides, and lactosylceramide) did not compete with GM1 for cellular binding. The relative specificity of the GM1-binding site was revealed by the lack of competition by lactosylceramide and very weak competition by disialoganglioside and trisialoganglioside that appeared to be due to a GM1 contamination in these preparations. Further characterization of the GM1-thymocyte interaction indicated that it was a Ca2+-dependent process, since chelating agents ethyleneglycolbis(ß-aminoethyl ether)-N,N'-tetraacetic acid and ethylenediaminetetraacetic acid inhibited the binding up to 75 to 80%, and the inhibition by ethyleneglycolbis(ß-aminoethyl ether)-N,N'-tetraacetic acid was reversed by the addition of excess of Ca2+. Also, there appeared to be no overlap of the GM1-binding site with the binding site for concanavalin A. Finally, a comparison of the amount of GM1 bound by leukemic and nonleukemic thymus cells revealed that the tumor cells have a higher capacity to bind GM1 molecules than do normal thymus cells on a per cell basis under several experimental conditions.
1 Supported by USPHS Grant CA 21631 from the National Cancer Institute.
2 To whom requests for reprints should be addressed.
Received 11/14/79. Accepted 5/12/80.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |